Last 47 quarters of trend data · Healthcare · Medical - Diagnostics & Research
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 42.84 | 31.41 | 40.72 | 54.91 | 46.98 | 36.94 | 35.47 | 39.45 | 45.11 | 49.92 | 48.04 | 59.81 | 43.21 | 47.03 | 49.03 | 49.75 | 37.88 | 56.21 | 60.25 | 87.10 | 76.59 |
| — | -15.0% | +14.8% | +39.2% | +4.1% | -26.0% | -26.2% | -34.0% | +4.4% | +6.2% | -2.0% | +20.2% | +14.1% | -16.3% | -18.6% | -42.9% | -50.5% | -16.7% | +15.7% | +40.1% | +31.7% | |
| P/S Ratio | 10.27 | 8.73 | 9.93 | 12.51 | 11.66 | 9.79 | 8.61 | 8.94 | 10.75 | 10.12 | 11.75 | 12.92 | 10.03 | 11.17 | 11.66 | 10.32 | 8.14 | 8.65 | 13.99 | 17.70 | 16.60 |
| — | -10.8% | +15.3% | +40.0% | +8.4% | -3.3% | -26.7% | -30.8% | +7.2% | -9.4% | +0.8% | +25.2% | +23.2% | +29.2% | -16.6% | -41.7% | -51.0% | -47.8% | +2.3% | +17.5% | +40.6% | |
| P/B Ratio | 28.16 | 26.34 | 29.13 | 34.00 | 33.01 | 29.78 | 23.76 | 21.39 | 25.93 | 25.71 | 28.89 | 31.38 | 28.31 | 38.56 | 49.92 | 56.17 | 57.57 | 65.12 | 73.16 | 82.21 | 71.22 |
| — | -11.6% | +22.6% | +58.9% | +27.3% | +15.8% | -17.8% | -31.8% | -8.4% | -33.3% | -42.1% | -44.1% | -50.8% | -40.8% | -31.8% | -31.7% | -19.2% | -11.0% | +21.0% | +19.7% | -7.8% | |
| P/FCF | 41.96 | 32.92 | 48.38 | 42.30 | 34.71 | 71.62 | 41.36 | 38.30 | 54.64 | 47.24 | 67.33 | 53.60 | 38.52 | 61.01 | 72.69 | 63.70 | 45.28 | 208.05 | 160.59 | 79.59 | 94.60 |
| — | -54.0% | +17.0% | +10.5% | -36.5% | +51.6% | -38.6% | -28.6% | +41.8% | -22.6% | -7.4% | -15.9% | -14.9% | -70.7% | -54.7% | -20.0% | -52.1% | +221.4% | +57.5% | +50.0% | +93.1% | |
| EV / EBITDA | 30.75 | 23.24 | 28.88 | 39.14 | 33.49 | 27.22 | 25.17 | 29.47 | 31.54 | 34.88 | 34.97 | 42.90 | 30.84 | 33.33 | 34.98 | 34.82 | 26.35 | 37.58 | 43.56 | 63.48 | 54.09 |
| — | -14.6% | +14.7% | +32.8% | +6.2% | -22.0% | -28.0% | -31.3% | +2.3% | +4.6% | -0.0% | +23.2% | +17.1% | -11.3% | -19.7% | -45.1% | -51.3% | -22.9% | +10.0% | +20.8% | +21.9% | |
| EV / EBIT | 33.16 | 25.37 | 31.83 | 43.68 | 36.89 | 29.78 | 27.77 | 32.87 | 34.78 | 38.64 | 37.91 | 47.40 | 33.93 | 36.43 | 38.46 | 39.19 | 29.38 | 43.40 | 48.18 | 72.24 | 60.40 |
| — | -14.8% | +14.6% | +32.9% | +6.1% | -22.9% | -26.7% | -30.7% | +2.5% | +6.1% | -1.4% | +20.9% | +15.5% | -16.1% | -20.2% | -45.7% | -51.4% | -18.9% | +10.5% | +21.5% | +19.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 64.0% | 63.4% | 60.3% | 61.8% | 62.6% | 62.4% | 59.8% | 61.1% | 61.9% | 61.5% | 58.4% | 59.9% | 60.7% | 60.3% | 58.5% | 60.2% | 59.7% | 59.6% | 57.0% | 58.4% |
| — | +2.3% | +1.5% | +0.9% | +1.2% | +1.2% | +1.5% | +2.5% | +2.1% | +1.9% | +2.0% | -0.3% | -0.6% | +1.6% | +1.2% | +2.7% | +3.2% | +0.9% | -1.5% | +0.3% | -0.3% | |
| Operating Margin | 31.6% | 35.0% | 31.8% | 28.9% | 32.1% | 33.6% | 31.7% | 27.4% | 31.2% | 26.3% | 31.0% | 27.2% | 30.1% | 31.4% | 31.1% | 27.3% | 29.1% | 20.8% | 29.7% | 24.9% | 27.9% |
| — | +4.0% | +0.3% | +5.5% | +3.1% | +27.9% | +2.2% | +0.8% | +3.6% | -16.2% | -0.4% | -0.5% | +3.4% | +50.8% | +4.9% | +10.0% | +4.3% | -33.7% | -6.8% | -3.2% | +17.1% | |
| Net Margin | 24.6% | 27.8% | 24.4% | 22.8% | 24.8% | 26.5% | 24.3% | 22.7% | 23.9% | 20.3% | 24.4% | 21.6% | 23.2% | 23.8% | 23.8% | 20.8% | 21.5% | 15.3% | 23.2% | 20.3% | 21.6% |
| — | +5.0% | +0.4% | +0.5% | +4.1% | +30.8% | -0.5% | +5.0% | +3.0% | -14.8% | +2.8% | +3.8% | +7.8% | +54.9% | +2.6% | +2.3% | -0.6% | -37.5% | -11.7% | -16.2% | +6.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.2% | 21.4% | 17.6% | 15.7% | 18.2% | 20.2% | 15.9% | 13.5% | 14.6% | 12.9% | 15.4% | 14.0% | 17.8% | 23.2% | 29.5% | 31.8% | 38.8% | 24.1% | 29.2% | 22.5% | 23.3% |
| — | +5.6% | +10.5% | +16.5% | +24.9% | +56.7% | +3.4% | -3.8% | -18.0% | -44.3% | -47.7% | -56.0% | -54.2% | -3.7% | +1.2% | +41.0% | +66.4% | -13.8% | -4.6% | -30.8% | -43.1% | |
| ROA | 31.9% | 9.9% | 8.3% | 7.4% | 8.2% | 9.0% | 7.5% | 6.5% | 6.9% | 6.0% | 7.1% | 6.1% | 7.1% | 7.9% | 7.7% | 6.4% | 6.9% | 5.1% | 7.7% | 6.7% | 7.3% |
| — | +10.3% | +10.8% | +13.2% | +18.8% | +49.6% | +4.7% | +6.1% | -3.4% | -23.9% | -7.6% | -4.1% | +3.3% | +55.6% | -0.1% | -5.3% | -5.6% | -40.6% | -12.7% | -16.2% | +0.1% | |
| ROIC | 42.5% | 12.8% | 11.0% | 9.5% | 10.7% | 11.5% | 10.2% | 8.5% | 10.0% | 8.8% | 10.3% | 8.8% | 9.8% | 10.7% | 10.5% | 8.8% | 9.9% | 7.5% | 11.3% | 9.5% | 10.9% |
| — | +11.8% | +7.0% | +11.7% | +6.4% | +30.2% | -0.9% | -2.5% | +2.3% | -17.3% | -1.3% | -0.8% | -0.8% | +41.3% | -7.4% | -6.9% | -9.7% | -44.1% | -20.7% | -14.3% | +7.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.67 | 0.68 | 0.71 | 0.67 | 0.71 | 0.85 | 0.73 | 0.62 | 0.62 | 0.68 | 0.68 | 0.72 | 0.88 | 1.05 | 1.57 | 2.41 | 3.16 | 3.28 | 2.01 | 1.49 | 1.27 |
| — | -19.9% | -2.9% | +8.5% | +15.5% | +25.5% | +7.4% | -14.0% | -29.8% | -35.9% | -56.6% | -70.2% | -72.2% | -67.8% | -21.8% | +61.6% | +148.2% | +142.0% | +41.2% | -5.8% | -43.2% | |
| Debt / EBITDA | 0.73 | 2.35 | 2.76 | 3.04 | 2.84 | 3.03 | 3.02 | 3.34 | 2.95 | 3.61 | 3.25 | 3.88 | 3.75 | 3.56 | 4.28 | 5.76 | 5.51 | 7.22 | 4.67 | 4.54 | 3.82 |
| — | -22.4% | -8.6% | -9.0% | -3.7% | -16.1% | -7.0% | -13.9% | -21.2% | +1.4% | -24.0% | -32.6% | -32.0% | -50.7% | -8.4% | +26.7% | +44.4% | +103.1% | +27.4% | -5.0% | -24.3% | |
| Current Ratio | 1.17 | 1.17 | 1.12 | 1.17 | 1.12 | 1.11 | 1.16 | 1.31 | 1.42 | 1.37 | 1.57 | 1.57 | 1.43 | 1.33 | 1.08 | 0.89 | 0.89 | 0.89 | 1.12 | 1.25 | 1.48 |
| — | +5.3% | -3.5% | -11.0% | -20.9% | -18.7% | -26.1% | -16.6% | -0.4% | +2.6% | +45.5% | +76.3% | +60.3% | +49.2% | -3.9% | -28.8% | -39.9% | -41.8% | -36.6% | -31.4% | -10.2% | |
| Quick Ratio | 0.84 | 0.87 | 0.82 | 0.84 | 0.81 | 0.79 | 0.81 | 0.95 | 1.03 | 1.03 | 1.16 | 1.17 | 1.02 | 0.89 | 0.71 | 0.59 | 0.59 | 0.61 | 0.81 | 0.90 | 1.07 |
| — | +9.6% | +1.6% | -12.1% | -21.6% | -23.0% | -30.2% | -18.6% | +1.3% | +16.0% | +63.2% | +97.4% | +72.6% | +45.7% | -12.3% | -34.0% | -44.8% | -47.8% | -42.3% | -38.6% | -13.2% | |
| Interest Coverage | 35.61 | 41.98 | 46.92 | 30.19 | 33.36 | 33.01 | 41.45 | 35.32 | 39.83 | 32.99 | 38.35 | 26.87 | 31.98 | 28.12 | 21.39 | 16.74 | 22.29 | 21.57 | 35.52 | 26.66 | 31.69 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IDXX stock.
IDEXX Laboratories, Inc.'s current P/E is 42.8x. The average P/E over the last 4 quarters is 43.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
IDEXX Laboratories, Inc.'s current operating margin is 31.6%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking IDEXX Laboratories, Inc.'s business trajectory between earnings reports.